Lancet Haematology最新文献

筛选
英文 中文
Amrecibart and cenvacibart for the prevention of catheter-related thrombosis (ROXI-CATH): a double-blind, randomised, placebo-controlled, phase 2 trial. amrecbart和cenvacibart用于预防导管相关性血栓形成(ROXI-CATH):一项双盲、随机、安慰剂对照的2期试验。
IF 20.4 1区 医学
Lancet Haematology Pub Date : 2026-11-07 DOI: 10.1016/S2352-3026(26)00249-8
Jeffrey I Zwicker, Aaron P Kithcart, Justin Kaplan, Poulabi Banerjee, Keshini Vyas, Dan Chalothorn, José G Raya, Siyu Li, Laura E Fredenburgh, Mihaela Mocan, Rosen Razboynikov, Lori G Morton, David E Gutstein, Kathryn M Musgrave, Gregory Piazza
{"title":"Amrecibart and cenvacibart for the prevention of catheter-related thrombosis (ROXI-CATH): a double-blind, randomised, placebo-controlled, phase 2 trial.","authors":"Jeffrey I Zwicker, Aaron P Kithcart, Justin Kaplan, Poulabi Banerjee, Keshini Vyas, Dan Chalothorn, José G Raya, Siyu Li, Laura E Fredenburgh, Mihaela Mocan, Rosen Razboynikov, Lori G Morton, David E Gutstein, Kathryn M Musgrave, Gregory Piazza","doi":"10.1016/S2352-3026(26)00249-8","DOIUrl":"https://doi.org/10.1016/S2352-3026(26)00249-8","url":null,"abstract":"<p><strong>Background: </strong>Peripherally inserted central catheters (PICCs) are often complicated by venous thromboembolism, yet no thromboprophylaxis is approved. Factor XI (FXI) inhibition might prevent catheter-associated venous thromboembolism without increasing bleeding. We evaluated the safety and efficacy of amrecibart and cenvacibart for preventing venous thromboembolism after PICC placement.</p><p><strong>Methods: </strong>ROXI-CATH is a double-blind, randomised, placebo-controlled, phase 2 trial conducted across 12 hospital centres in Bulgaria, Canada, Israel, Romania, the UK, and the USA. Eligible participants aged 18 years or older undergoing PICC insertion, with the PICC expected to remain for at least 14 days, and an Eastern Cooperative Oncology Group performance status of 2 or less were randomly assigned (1:1:1) using a permuted block design and stratified by site and diagnosis of active cancer to receive a single intravenous infusion of amrecibart (300 mg; anti-FXI A2 domain monoclonal antibody), cenvacibart (250 mg; anti-FXI catalytic domain monoclonal antibody), or placebo. Participants, principal investigators, and study site staff were masked to treatment assignment. The primary efficacy outcome was adjudicated venous thromboembolism (symptomatic or asymptomatic PICC-associated deep vein thrombosis or superficial vein thrombosis, or pulmonary embolism, including pulmonary embolism-related death) up to day 14. Ultrasounds were performed on days 7 and 14. The key secondary efficacy outcome was adjudicated thrombosis detected by ultrasound in the upper extremity with the PICC up to day 14. The primary safety outcome was site-reported treatment-emergent adverse events up to the end of the study. The key secondary safety outcomes were adjudicated major and clinically relevant non-major (CRNM) bleeding up to day 14. Efficacy analyses were performed in the full analysis set, which consisted of all randomly assigned participants who received any study drug and with any evaluable post-baseline ultrasound or a confirmed episode of venous thromboembolism. Safety analyses were performed in the safety analysis set, which included all randomly assigned participants who received any study drug (as treated). This trial is registered with ClinicalTrials.gov, NCT06299111 (completed; these analyses were performed after database lock on May 6, 2026).</p><p><strong>Findings: </strong>Between Sept 20, 2024, and Dec 19, 2025, 240 participants were screened, and 195 were randomly assigned to amrecibart (n=65), cenvacibart (n=66), or placebo (n=64). One participant in the placebo group who did not receive study treatment and had no evaluable ultrasound was excluded from the full analysis set. The median follow-up time was 100 days (IQR 100-103). The median age was 60 years (49-69), and 89 (46%) of 194 participants were female, 105 (54%) were male, and 192 (99%) were White. Adjudicated venous thromboembolism up to day 14 occured in 13 (20%) of 65 p","PeriodicalId":48726,"journal":{"name":"Lancet Haematology","volume":" ","pages":""},"PeriodicalIF":20.4,"publicationDate":"2026-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149372004","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Improved survival after allo-HCT in Hodgkin lymphoma: true progress or time-dependent confounding? 霍奇金淋巴瘤同种异体hct后生存率的提高:真正的进展还是时间依赖的混淆?
IF 20.4 1区 医学
Lancet Haematology Pub Date : 2026-11-01 DOI: 10.1016/S2352-3026(26)00251-6
Qianpeng Li, Baohong Wang, Shaoqiang Wang
{"title":"Improved survival after allo-HCT in Hodgkin lymphoma: true progress or time-dependent confounding?","authors":"Qianpeng Li, Baohong Wang, Shaoqiang Wang","doi":"10.1016/S2352-3026(26)00251-6","DOIUrl":"https://doi.org/10.1016/S2352-3026(26)00251-6","url":null,"abstract":"","PeriodicalId":48726,"journal":{"name":"Lancet Haematology","volume":"13 11","pages":"e783"},"PeriodicalIF":20.4,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149301302","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Phenotype, treatment, and determinants of prognosis in Erdheim-Chester disease: an international, retrospective, cohort study. 埃尔德海姆-切斯特病的表型、治疗和预后决定因素:一项国际、回顾性、队列研究。
IF 20.4 1区 医学
Lancet Haematology Pub Date : 2026-11-01 Epub Date: 2026-10-15 DOI: 10.1016/S2352-3026(26)00247-4
Francesco Pegoraro, Francesco Peyronel, Matthias Papo, Jerome Razanamahery, Francesco Catamerò, Giulia Palazzini, Ilaria Fibbi, Emmanuel Ledoult, Tanguy Le Scornet, Mathilde de Menthon, Etienne Rivière, Achille Aouba, Fleur Cohen-Aubart, Zahir Amoura, Ahmed Idbaih, Xavier Solanich, Polyzois Makras, Vanderson Rocha, Ofer Shpilberg, Oshrat Hershkovitz-Rokah, David L Pottinger, Laura E M Eurelings, Jan A van Laar, Astrid G S van Halteren, Michael Girschikofsky, Matthew J Koster, Nehaal Ahmed, Dongni Yi, Kristian Bowles, Alessandro Tomelleri, Corrado Campochiaro, Kevin O'Brien, Juvianee Estrada-Veras, Pierre Hirsch, Elena Sieni, Gaurav Goyal, Omar Abdel-Wahab, Jean-François Emile, Matthew Collin, Lorenzo Dagna, Ronald S Go, Eli L Diamond, Augusto Vaglio, Julien Haroche
{"title":"Phenotype, treatment, and determinants of prognosis in Erdheim-Chester disease: an international, retrospective, cohort study.","authors":"Francesco Pegoraro, Francesco Peyronel, Matthias Papo, Jerome Razanamahery, Francesco Catamerò, Giulia Palazzini, Ilaria Fibbi, Emmanuel Ledoult, Tanguy Le Scornet, Mathilde de Menthon, Etienne Rivière, Achille Aouba, Fleur Cohen-Aubart, Zahir Amoura, Ahmed Idbaih, Xavier Solanich, Polyzois Makras, Vanderson Rocha, Ofer Shpilberg, Oshrat Hershkovitz-Rokah, David L Pottinger, Laura E M Eurelings, Jan A van Laar, Astrid G S van Halteren, Michael Girschikofsky, Matthew J Koster, Nehaal Ahmed, Dongni Yi, Kristian Bowles, Alessandro Tomelleri, Corrado Campochiaro, Kevin O'Brien, Juvianee Estrada-Veras, Pierre Hirsch, Elena Sieni, Gaurav Goyal, Omar Abdel-Wahab, Jean-François Emile, Matthew Collin, Lorenzo Dagna, Ronald S Go, Eli L Diamond, Augusto Vaglio, Julien Haroche","doi":"10.1016/S2352-3026(26)00247-4","DOIUrl":"10.1016/S2352-3026(26)00247-4","url":null,"abstract":"<p><strong>Background: </strong>Erdheim-Chester disease is a rare histiocytosis driven by MAPK pathway gene mutations. Its clinical presentation is heterogeneous, and there is a shortage of data on natural history and prognosis. We aimed to characterise clinical presentation, associated conditions, treatments, outcomes, and determinants of prognosis in a large international Erdheim-Chester disease cohort.</p><p><strong>Methods: </strong>We conducted an international, retrospective, cohort study of patients with biopsy-proven Erdheim-Chester disease diagnosed between Jan 1, 1985, and Dec 31, 2024. Data were collected in ten countries by participating investigators from referral centre records using standardised criteria, and were collected by participating investigators from referral centre records using standardised criteria. Patients with available data on treatment and outcome, and a minimum follow-up duration of 6 months, without excluding those who died before month 6, were included. Outcomes were response to treatment and overall survival. Mortality predictors were assessed using multivariable Cox proportional hazards regression.</p><p><strong>Findings: </strong>From Jan 1 to Dec 31, 2025, we included 1174 patients (males 801 [68%], females 373 [32%]), whose median age at diagnosis was 58 (IQR 47-67) years. Multisystem disease (at least four organs) was present in 724 (62%) of 1174 patients, the most frequently affected sites being long bones (940 [80%] patients), retroperitoneum (742 [63%] patients), large vessels (540 [46%] patients), central nervous system (446 [38%] patients), and heart (412 [35%] patients). 643 (62%) of 1043 tested patients were BRAF<sup>V600E</sup> mutated, and 250 (36%) of 690 patients had clonal haematopoiesis. Overlap with other histiocytoses occurred in 161 (14%) of 1174 patients, whereas 321 (27%) patients had second cancer. First-line therapies most commonly included interferon-α (362 [34%] of 1057 patients) or targeted therapies (BRAF/MEK inhibitors 350 [33%] patients), with targeted therapies achieving the highest objective response rates (286 [74%] of 387 patients for BRAF inhibitors, and 185 [71%] of 262 patients for MEK inhibitors). After a median of 49 months (IQR 20-91), 261 (22%) patients died. Multivariable analysis identified older age (p<0·0001), neurodegeneration (HR 4·2, 95% CI 2·4-7·1; p<0·0001), high C-reactive protein (3·8, 1·6-9·1; p=0·0022), second haematological cancer (3·0, 1·5-6·0; p=0·0023), and no response to treatment (2·8, 1·6-5·1; p=0·0006) as independent predictors of mortality.</p><p><strong>Interpretation: </strong>In a large Erdheim-Chester disease cohort spanning multiple eras, mortality remains substantial. These findings support early identification of patients with high-risk features and development of risk-adapted follow-up and treatment strategies.</p><p><strong>Funding: </strong>None.</p>","PeriodicalId":48726,"journal":{"name":"Lancet Haematology","volume":" ","pages":"e800-e809"},"PeriodicalIF":20.4,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149197404","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Emerging novel therapies for the treatment of hereditary haemorrhagic telangiectasia. 新兴的治疗遗传性出血性毛细血管扩张的新疗法。
IF 20.4 1区 医学
Lancet Haematology Pub Date : 2026-11-01 Epub Date: 2026-10-11 DOI: 10.1016/S2352-3026(26)00190-0
Hanny Al-Samkari
{"title":"Emerging novel therapies for the treatment of hereditary haemorrhagic telangiectasia.","authors":"Hanny Al-Samkari","doi":"10.1016/S2352-3026(26)00190-0","DOIUrl":"10.1016/S2352-3026(26)00190-0","url":null,"abstract":"<p><p>Hereditary haemorrhagic telangiectasia is the second most common heritable bleeding disorder worldwide, with a prevalence more than twice that of haemophilia, and is the most morbid inherited bleeding disorder of women. As an autosomal dominant vasculopathy due to dysregulated angiogenic signalling, patients with hereditary haemorrhagic telangiectasia develop telangiectasias and arteriovenous malformations which cause numerous complications. These complications include moderate-to-severe chronic epistaxis, gastrointestinal bleeding, iron deficiency anemia, and requirement for intravenous iron or red cell transfusion. Additionally, incidence of intracranial haemorrhage is high and morbid non-bleeding complications, such as venous thromboembolism, stroke, and liver disease, are common. Despite this serious disease burden, hereditary haemorrhagic telangiectasia remains without licensed therapies worldwide. However, many novel, investigational agents targeting vascular and haemostatic systems are now rapidly undergoing formal development specifically in hereditary haemorrhagic telangiectasia. These agents include the selective AKT1/AKT2 inhibitor engasertib, AKT1-selective inhibitors ATV-1601 and TER-4480, plasminogen siRNA agent ALN-6400, activin receptor-like kinase 1-bone morphogenetic protein receptor type II (ALK1-BMPRII) bispecific clustering antibody DIAG723, and apelin receptor antagonist antibody TX2100. This comprehensive Review provides essential background information and illustrations summarising relevant hereditary haemorrhagic telangiectasia pathophysiology, followed by focused, detailed discussions of each of the novel agents in development, including the mechanisms, therapeutic rationale, clinical trial programmes, and potential therapeutic effects.</p>","PeriodicalId":48726,"journal":{"name":"Lancet Haematology","volume":" ","pages":"e865-e875"},"PeriodicalIF":20.4,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149170407","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Incidence of clinically diagnosed infections in children with sickle cell anaemia treated with oral hydroxyurea in Angola, DR Congo, Kenya, and Uganda: a retrospective cohort study from the REACH trial. 安哥拉、刚果民主共和国、肯尼亚和乌干达口服羟脲治疗的镰状细胞贫血儿童临床诊断感染发生率:一项来自REACH试验的回顾性队列研究
IF 20.4 1区 医学
Lancet Haematology Pub Date : 2026-11-01 Epub Date: 2026-10-07 DOI: 10.1016/S2352-3026(26)00246-2
Thomas N Williams, Luke R Smart, George Tomlinson, Brígida Santos, Léon Tshilolo, Peter Olupot-Olupot, Banu Aygun, Susan E Stuber, Adam Lane, Teresa Latham, Russell E Ware
{"title":"Incidence of clinically diagnosed infections in children with sickle cell anaemia treated with oral hydroxyurea in Angola, DR Congo, Kenya, and Uganda: a retrospective cohort study from the REACH trial.","authors":"Thomas N Williams, Luke R Smart, George Tomlinson, Brígida Santos, Léon Tshilolo, Peter Olupot-Olupot, Banu Aygun, Susan E Stuber, Adam Lane, Teresa Latham, Russell E Ware","doi":"10.1016/S2352-3026(26)00246-2","DOIUrl":"10.1016/S2352-3026(26)00246-2","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;Hydroxyurea is widely used in the first-line treatment of sickle cell anaemia; however, its mildly myelosuppressive effects when used at therapeutic doses have led to suggestions that treatment with hydroxyurea might increase the risk of infection. To address this question, we have investigated the incidence of clinically diagnosed infections among children within the Realizing Effectiveness Across Continents with Hydroxyurea (REACH) trial during various phases of hydroxyurea treatment.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;REACH (NCT01966731 and NCT06171217) is an ongoing, phase 1/2, open-label, multicentre treatment trial of children with sickle cell anaemia with 2 months of screening followed by oral hydroxyurea at a fixed dose for 6 months and then dose escalation to the maximum tolerated dose (MTD). The current international, retrospective cohort study included children aged 1-10 years with sickle cell anaemia who were recruited and enrolled into REACH from four hospitals in Angola, DR Congo, Kenya, and Uganda and who had previously been followed up within the trial. Clinically diagnosed infections were characterised by likely aetiology and severity and incidence rate ratios (IRR) were then computed across time and during dosing phases as protocol-specified outcomes. The primary outcome of the current analysis was the incidence of clinically diagnosed infections, which was stratified by hydroxyurea treatment phase and assessed in all children who started fixed-dose hydroxyurea treatment. Rates of each clinically diagnosed infection (per 100 person-years of observation [PYO]) were calculated by age group and dosing phase.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Findings: &lt;/strong&gt;Between July 4, 2014, and Nov 11, 2016, 635 children were enrolled in the trial. 606 children (296 [49%] female and 310 [51%] male) completed screening and began treatment with hydroxyurea. Overall, 5493 infections occurred across 5638 PYO, with an incidence rate of 97·4/100 PYO. Among non-malarial infections, rates declined from the screening to fixed-dose phase (adjusted IRR 0·81 [95% CI 0·67-0·98]) and decreased further from the screening to the MTD phase (0·51 [0·43-0·61]; p&lt;0·0001). Statistically significant decreases across the fixed-dose, dose-escalation, and MTD phases, respectively, were observed in the adjusted IRRs for upper respiratory tract infections (IRR 0·84 [95% CI 0·62-1·14], 0·77 [0·58-1·03], and 0·64 [0·47-0·88]; p=0·0051), lower respiratory tract infections (1·26 [0·69-2·31], 0·60 [0·32-1·12], and 0·45 [0·23-0·89]; p=0·021), bacterial skin or nail infections (0·58 [0·26-1·30], 0·32 [0·15-0·68], and 0·31 [0·14-0·66]; p=0·0025), and non-specific infectious syndromes (0·80 [0·58-1·11], 0·47 [0·35-0·63], and 0·39 [0·28-0·53]; p&lt;0·0001). A similar decrease was observed for the adjusted IRR of grade 3 or higher infections across the fixed-dose, dose-escalation, and MTD phases, respectively (0·65 [0·42-1·00], 0·20 [0·13-0·32], and 0·48 [0·32-0·73]; p=0·","PeriodicalId":48726,"journal":{"name":"Lancet Haematology","volume":" ","pages":"e789-e799"},"PeriodicalIF":20.4,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149128801","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Should plasma cell leukaemia be classified as multiple myeloma? 浆细胞白血病应归入多发性骨髓瘤吗?
IF 20.4 1区 医学
Lancet Haematology Pub Date : 2026-11-01 Epub Date: 2026-09-28 DOI: 10.1016/S2352-3026(26)00252-8
Pellegrino Musto, Niels W C J van de Donk
{"title":"Should plasma cell leukaemia be classified as multiple myeloma?","authors":"Pellegrino Musto, Niels W C J van de Donk","doi":"10.1016/S2352-3026(26)00252-8","DOIUrl":"10.1016/S2352-3026(26)00252-8","url":null,"abstract":"","PeriodicalId":48726,"journal":{"name":"Lancet Haematology","volume":" ","pages":"e784-e785"},"PeriodicalIF":20.4,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149076170","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Hydroxyurea benefits for sickle cell anaemia in sub-Saharan Africa. 羟基脲有益于撒哈拉以南非洲的镰状细胞性贫血。
IF 20.4 1区 医学
Lancet Haematology Pub Date : 2026-11-01 Epub Date: 2026-10-07 DOI: 10.1016/S2352-3026(26)00261-9
Nancy S Green, Jessica E Justman
{"title":"Hydroxyurea benefits for sickle cell anaemia in sub-Saharan Africa.","authors":"Nancy S Green, Jessica E Justman","doi":"10.1016/S2352-3026(26)00261-9","DOIUrl":"10.1016/S2352-3026(26)00261-9","url":null,"abstract":"","PeriodicalId":48726,"journal":{"name":"Lancet Haematology","volume":" ","pages":"e779-e781"},"PeriodicalIF":20.4,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149128757","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Decitabine plus busulfan-cyclophosphamide versus busulfan-cyclophosphamide myeloablative conditioning before allogeneic haematopoietic stem cell transplantation for reducing risk of relapse in adult KMT2A‑rearranged leukaemia in China: an open-label, multicentre, randomised phase 3 trial. 在中国,异基因造血干细胞移植前地西他滨加布磺胺-环磷酰胺与布磺胺-环磷酰胺清髓调节降低成人KMT2A重排白血病复发风险:一项开放标签、多中心、随机3期试验
IF 20.4 1区 医学
Lancet Haematology Pub Date : 2026-11-01 DOI: 10.1016/S2352-3026(26)00250-4
Zhongli Hu, Zhiping Fan, Min Dai, Hai He, Hua Jin, Zhiqiang Sun, Fen Huang, Na Xu, Qianwei Liu, Yiqing Li, Ying Dong, Ping Zhu, Can Liu, Yunxin Zeng, Jing Sun, Ruijuan Sun, Li Xuan, Qifa Liu
{"title":"Decitabine plus busulfan-cyclophosphamide versus busulfan-cyclophosphamide myeloablative conditioning before allogeneic haematopoietic stem cell transplantation for reducing risk of relapse in adult KMT2A‑rearranged leukaemia in China: an open-label, multicentre, randomised phase 3 trial.","authors":"Zhongli Hu, Zhiping Fan, Min Dai, Hai He, Hua Jin, Zhiqiang Sun, Fen Huang, Na Xu, Qianwei Liu, Yiqing Li, Ying Dong, Ping Zhu, Can Liu, Yunxin Zeng, Jing Sun, Ruijuan Sun, Li Xuan, Qifa Liu","doi":"10.1016/S2352-3026(26)00250-4","DOIUrl":"https://doi.org/10.1016/S2352-3026(26)00250-4","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;An unmet need persists for optimal myeloablative conditioning before allogeneic haematopoietic stem cell transplantation (HSCT) in adult KMT2A‑rearranged leukaemia. We investigated whether decitabine plus busulfan-cyclophosphamide (DAC-BuCy) conditioning reduced the risk of relapse compared with busulfan-cyclophosphamide (BuCy) conditioning.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;In this open-label, randomised, phase 3 trial at eight transplantation centres in China, eligible patients were aged 14-65 years, had morphologically confirmed KMT2A-rearranged leukaemia, and had an Eastern Cooperative Oncology Group performance status of 0-2. Patients were randomly assigned (1:1) before HSCT to DAC-BuCy (intravenous decitabine 20 mg/m&lt;sup&gt;2&lt;/sup&gt; once a day on days -14 to -10, intravenous busulfan 3·2 mg/kg once a day on days -7 to -4, and intravenous cyclophosphamide 60 mg/kg once a day on days -3 to -2) or BuCy (same dose and duration of busulfan and cyclophosphamide). Randomisation was done with permuted blocks (block size four) with no stratification and was implemented through an independent, interactive, web-based response system. The primary endpoint was 2-year cumulative incidence of relapse in the intention-to-treat population. Safety was assessed in all patients who received treatment. This trial is registered with ClinicalTrials.gov (NCT03596892) and is complete.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Findings: &lt;/strong&gt;Between May 1, 2019, and Jan 31, 2023, 130 patients were randomised to receive a DAC-BuCy (n=65; 34 [52%] female and 31 [48%] male) or BuCy (n=65; 29 [45%] female and 36 [55%] male) regimen. Median follow-up was 34·7 months (IQR 30·2-52·5). 2-year cumulative incidence of relapse was 12% (95% CI 6-22) in the DAC-BuCy group and 29% (19-41) in the BuCy group (hazard ratio 0·41 [0·20-0·87]; p=0·017). The most common grade 3-5 adverse events were infections or infestations (DAC-BuCy group 27 [42%] and BuCy group 25 [38%]), acute graft-versus-host disease (DAC-BuCy group 23 [35%] and BuCy group 22 [34%]), and gastrointestinal disorders (DAC-BuCy group 14 [22%] and BuCy group 15 [23%]). Four (6%) patients in the DAC-BuCy group and five (8%) patients in the BuCy group died from adverse events, of which two were due to regimen-related toxicities: one nervous system disorder in the DAC-BuCy group and one cardiac disorder in the BuCy group.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Interpretation: &lt;/strong&gt;The addition of decitabine to BuCy conditioning reduced the risk of relapse with an acceptable safety profile in adult patients with KMT2A‑rearranged leukaemia and could be a suitable therapeutic option for this population.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Funding: &lt;/strong&gt;The National Natural Science Foundation of China, the National Key Research and Development Program of China, the Science and Technology Program of Guangdong Province, the Non-communicable Chronic Diseases-National Science and Technology Major Project, the Natural Science Foundation of Guangdong Province, the Sc","PeriodicalId":48726,"journal":{"name":"Lancet Haematology","volume":"13 11","pages":"e810-e821"},"PeriodicalIF":20.4,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149301323","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Improved survival after allo-HCT in Hodgkin lymphoma: true progress or time-dependent confounding? - Authors' reply. 霍奇金淋巴瘤同种异体hct后生存率的提高:真正的进展还是时间依赖的混淆?-作者的答复。
IF 20.4 1区 医学
Lancet Haematology Pub Date : 2026-11-01 DOI: 10.1016/S2352-3026(26)00255-3
Ali Bazarbachi, Mathilde Fekom, Anna Sureda
{"title":"Improved survival after allo-HCT in Hodgkin lymphoma: true progress or time-dependent confounding? - Authors' reply.","authors":"Ali Bazarbachi, Mathilde Fekom, Anna Sureda","doi":"10.1016/S2352-3026(26)00255-3","DOIUrl":"https://doi.org/10.1016/S2352-3026(26)00255-3","url":null,"abstract":"","PeriodicalId":48726,"journal":{"name":"Lancet Haematology","volume":"13 11","pages":"e783-e784"},"PeriodicalIF":20.4,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149301353","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
When inflammation conceals malignancy in the urinary bladder. 当炎症掩盖了膀胱中的恶性肿瘤。
IF 20.4 1区 医学
Lancet Haematology Pub Date : 2026-10-30 DOI: 10.1016/S2352-3026(26)00134-1
Khadeeja Thasneem, Lakshmy S Kumar, K P Aravindan, Vijayalakshmi Nair
{"title":"When inflammation conceals malignancy in the urinary bladder.","authors":"Khadeeja Thasneem, Lakshmy S Kumar, K P Aravindan, Vijayalakshmi Nair","doi":"10.1016/S2352-3026(26)00134-1","DOIUrl":"https://doi.org/10.1016/S2352-3026(26)00134-1","url":null,"abstract":"","PeriodicalId":48726,"journal":{"name":"Lancet Haematology","volume":" ","pages":""},"PeriodicalIF":20.4,"publicationDate":"2026-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149301392","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书